z-logo
open-access-imgOpen Access
Esmolol Administration for the Treatment of Refractory Ventricular Fibrillation
Author(s) -
Kazım Karaaslan,
Tarık Umutoğlu,
Ufuk Topuz,
Yasin Ay
Publication year - 2016
Publication title -
bezmialem science
Language(s) - English
Resource type - Journals
ISSN - 2148-2373
DOI - 10.14235/bs.2016.570
Subject(s) - medicine , esmolol , refractory (planetary science) , ventricular fibrillation , cardiology , refractory period , anesthesia , heart rate , metallurgy , materials science , blood pressure
Ventricular fibrillation (VF) after releasing an aortic cross clamp in patients undergoing open heart surgery procedures is not rare. Ischemia-reperfusion injury after release of the aortic clamp, increased adrenergic tone, and insufficient protection of the myocardium are the possible causes. Amiodarone, lidocaine, and beta blockers have been added to the cardioplegia solutions as a preventive measure for reperfusion VF. We report a case of life-threatening, shock-resistant VF during the weaning period of a cardiopulmonary bypass (CPB) in a 61-year-old male who underwent a mitral valve repair surgery for mitral valve regurgitation. After several defibrillation attempts, refractory VF was turned to normal sinus rhythm shortly after ultra-short acting, beta blocking agent esmolol administration. CPB was terminated successfully following this. In conclusion, VF is still a major problem for clinicians and the treatment of refractory VF is not well defined. In contrast with the absence of the sufficient randomized controlled human studies, theoretically beta blockers could be a choice alternative for shock refractory VF.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom